arrow
A

Adam Mendizabal

the emmes company
H指数:44
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变及FLT3-ITD急性髓系白血病中可测量的微小残留病的影响

2025-07-030
OAAI
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial
2021-09-032
OAAI
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

急性髓性白血病和骨髓增生异常综合征中造血细胞移植的清髓性与低强度预处理-BMT CTN 0901临床试验的长期随访

2021-06-0188
OAAI
A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801
2018-06-2842
OAAI
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)
2017-11-10153
OAAI
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, PlaceboControlled Clinical Trial
2017-07-17128
OAAI
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty
2017-04-2179
OAAI
Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally? An Analysis From the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis ( POSEIDON) Randomized Trial
2014-04-1199
OAAI
Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting
2014-04-11292
OAAI
Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy The TAC-HFT Randomized Trial

经心内膜间充质干细胞和骨髓单个核细胞治疗缺血性心肌病的tac-hft随机试验

2014-01-01465
OAAI
Comparison of Allogeneic vs Autologous Bone Marrow-Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy The POSEIDON Randomized Trial
2012-12-121.0K
OAAI
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy
2011-03-01131
PREAI